CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 19 enrolled
Drug / intervention
lubiprostonedrug
Likely dose
lubiprostone 24 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01460225
NCT01460225Phase 4Completed
CompareCT.gov

Effects of Lubiprostone on Gastric Sensory and Motor Function in Patients With Chronic Idiopathic Constipation

Dartmouth-Hitchcock Medical Center·interventional·Posted Oct 26, 2011·Updated Jul 13, 2018

In Brief

A Phase 4 clinical trial evaluating lubiprostone for Chronic Idiopathic Constipation. Completed, enrolled 19 participants across 1 site.

Detailed Summary

This prospective study is designed to evaluate how lubiprostone may affect gastric motor and sensory function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Idiopathic Constipation
CountriesUnited States
CollaboratorsTakeda Pharmaceuticals North America, Inc.

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 26, 2011
Enrollment StartSep 1, 2007
Primary CompletionDec 1, 2010
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 14.7 years ago

Interventions

lubiprostonedrug

24 micrograms twice daily for 1 week